The group's principal activities are to research, develop and commercialize biotechnology and biomaterial in the health care area. The group through its subsidiaries manufactures and markets bone graft substitute and other patented biomaterials. The group has developed autologous fibrin glue that utilizes the patient's own blood, there by eliminating the risk of viral transmission. The group has developed a product biocoral(R) for treatment of bone fractures due to osteoporosis. The group has begun clinical trials of its products. The group has patient applications in various countries such as Europe, Canada, the United States, Japan, Australia and Switzerland.
